Read More

Small-Cap Firm Century Therapeutics’ Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.

IPSC

Read More

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.

ABSI